{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:00:08Z","timestamp":1777456808770,"version":"3.51.4"},"reference-count":68,"publisher":"The Japan Society of Coloproctology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Anus Rectum Colon"],"published-print":{"date-parts":[[2025,1,25]]},"DOI":"10.23922\/jarc.2024-067","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:12:58Z","timestamp":1737756778000},"page":"10-19","source":"Crossref","is-referenced-by-count":2,"title":["Management of Anal Fistula with Crohn's Disease"],"prefix":"10.23922","volume":"9","author":[{"given":"Shota","family":"Takano","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Center, Coloproctology Center Takano Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Coloproctology Center Takano Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Tamaoka","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Coloproctology Center Takano Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Coloproctology Center Takano Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasue","family":"Irei","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Coloproctology Center Takano Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriyuki","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Coloproctology Center Takano Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10009","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Buchmann P, Keighley MR, Allan RN, et al. Natural history of perianal Crohn's disease. Ten year follow-up: a plea for conservatism. Am J Surg. 1980 Nov;140 (5):642-4.","DOI":"10.1016\/0002-9610(80)90048-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980 Jun;21 (6):525-7.","DOI":"10.1136\/gut.21.6.525"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018 Apr;113 (4):481-517.","DOI":"10.1038\/ajg.2018.27"},{"key":"4","unstructured":"4. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus on surgery for Crohn's disease. J Crohns Colitis. 2018 Jan;12 (1):1-16."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122 (4):875-80.","DOI":"10.1053\/gast.2002.32362"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn's disease: future directions. Gut. 2018 Jun;67 (6):1181-94.","DOI":"10.1136\/gutjnl-2017-314918"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016 Apr;14 (2):111-9.","DOI":"10.5217\/ir.2016.14.2.111"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chun J, Im JP, Kim JW, et al. Association of perianal fistulas with clinical features and prognosis of Crohn's disease in Korea: results from the CONNECT study. Gut Liver. 2018 Sep;12 (5):544-54.","DOI":"10.5009\/gnl18157"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Molendijk I, Nuij VJAA, van der Meulen-de Jong AE, et al. Disappointing durable remission rates in complex Crohn's disease fistula. Inflamm Bowel Dis. 2014 Nov;20 (11):2022-8.","DOI":"10.1097\/MIB.0000000000000148"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn's disease in a population-based cohort. Dis Colon Rectum. 2012 Jun;55 (7):773-7.","DOI":"10.1097\/DCR.0b013e31825228b0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamamoto T, Nakase H, Watanabe K, et al. Diagnosis and clinical features of perianal lesions in newly diagnosed Crohn's disease: subgroup analysis from inception cohort registry study of patients with Crohn's disease (iCREST-CD). J Crohns Colitis. 2023 Aug;17 (8):1193-206.","DOI":"10.1093\/ecco-jcc\/jjad038"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Atienza P, Ksiaa M. Particular aspects of proctology for anoperineal lesions in Crohn's disease. J Visc Surg. 2015 Apr;152 (2):S45-S53.","DOI":"10.1016\/j.jviscsurg.2015.01.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Marzo M, Felice C, Pugliese D, et al. Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol. 2015 Feb;21 (5):1394-403.","DOI":"10.3748\/wjg.v21.i5.1394"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Dignass AU. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis. 2001 Feb;7 (1):68-77.","DOI":"10.1097\/00054725-200102000-00014"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn's disease. World J Gastrointest Pathophysiol. 2014 Aug;5 (3):205-12.","DOI":"10.4291\/wjgp.v5.i3.205"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov;125 (5):1508-30.","DOI":"10.1016\/j.gastro.2003.08.025"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zawadzki A, Starck M, Bohe M, et al. A unique 3D endoanal ultrasound feature of perianal Crohn's fistula: the "Crohn ultrasound fistula sign". Colorectal Dis. 2012 Sep;14 (9):e608-11.","DOI":"10.1111\/j.1463-1318.2012.03047.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003 Mar;9 (2):98-103.","DOI":"10.1097\/00054725-200303000-00003"},{"key":"19","unstructured":"19. Adamina M, Minozzi S, Warusavitarne J, et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J Crohns Colitis [Internet]. 2024 Jun 15 [cited 2024 July 25]. Available from: https:\/\/academic.oup.com\/ecco-jcc\/advance-article\/doi\/10.1093\/ecco-jcc\/jjae089\/7693896."},{"key":"20","unstructured":"20. Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease? Ann Gastroenterol. 2018 Jul;31 (4):413-24."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Adler J, Lin CC, Gadepalli SK, et al. Association between steroid-sparing therapy and the risk of perianal fistulizing complications among young patients with Crohn disease. JAMA Netw Open. 2020 Jun;3 (6):e207378.","DOI":"10.1001\/jamanetworkopen.2020.7378"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jeon M, Song K, Koo J, et al. Evaluation of a seton procedure combined with infliximab therapy (Early vs. Late) in perianal fistula with Crohn disease. Ann Coloproctol. 2019 Oct;35 (5):249-53.","DOI":"10.3393\/ac.2018.11.23.1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003 Dec;18 (11-12):1113-20.","DOI":"10.1046\/j.1365-2036.2003.01793.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004 Dec;20 (11-12):1329-36.","DOI":"10.1111\/j.1365-2036.2004.02247.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014 Feb;63 (2):292-9.","DOI":"10.1136\/gutjnl-2013-304488"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May;340 (18):1398-405.","DOI":"10.1056\/NEJM199905063401804"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb;350 (9):876-85.","DOI":"10.1056\/NEJMoa030815"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chande N, Townsend CM, Parker CE, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2016 Oct;10 (10):CD000545.","DOI":"10.1002\/14651858.CD000545.pub5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995 Jul;123 (2):132-42.","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980 May;302 (18):981-7.","DOI":"10.1056\/NEJM198005013021801"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr;362 (15):1383-95.","DOI":"10.1056\/NEJMoa0904492"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994 Feb;39 (2):374-80.","DOI":"10.1007\/BF02090211"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug;125 (2):380-8.","DOI":"10.1016\/S0016-5085(03)00877-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Bermejo F, Guerra I, Algaba A, et al. Pharmacological approach to the management of Crohn's disease patients with perianal disease. Drugs. 2018 Jan;78 (1):1-18.","DOI":"10.1007\/s40265-017-0842-x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the Classic-I trial. Gastroenterology. 2006 Feb;130 (2):323-33.","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun;146 (12):829-38.","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan;132 (1):52-65.","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul;58 (7):940-8.","DOI":"10.1136\/gut.2008.159251"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov;38 (10):1236-47.","DOI":"10.1111\/apt.12499"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010 Nov;32 (10):1228-39.","DOI":"10.1111\/j.1365-2036.2010.04466.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Malian A, Rivi\u00e8re P, Bouchard D, et al. Pedictors of perianal fistula relapse in Crohn's disease. Inflamm Bowel Dis. 2020 May;26 (6):926-31.","DOI":"10.1093\/ibd\/izz200"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Legu\u00e9 C, Brochard C, Bessi G, et al. Outcomes of perianal fistulising Crohn's disease following Anti-TNF\u03b1 treatment discontinuation. Inflamm Bowel Dis. 2018 May;24 (6):1107-13.","DOI":"10.1093\/ibd\/izy008"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Mak JWY, Tang W, Yip TCF, et al. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. Aliment Pharmacol Ther. 2019 Dec;50 (11-12):1195-203.","DOI":"10.1111\/apt.15547"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul;357 (3):228-38.","DOI":"10.1056\/NEJMoa067594"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul;357 (3):239-50.","DOI":"10.1056\/NEJMoa062897"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Schreiber S, Lawrance IC, Thomsen O\u00d8, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan;33 (2):185-93.","DOI":"10.1111\/j.1365-2036.2010.04509.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Sands BE, Gasink C, Jacobstein D, et al. Fistula healing in pivotal studies of ustekinumab in Crohn's disease. Gastroenterology. 2017 Apr;152 (5):S185.","DOI":"10.1016\/S0016-5085(17)30930-7"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Lee MJ, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018 Dec;16 (12):1879-92.","DOI":"10.1016\/j.cgh.2018.01.030"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn's disease: the BioLAP multicenter study from the GETAID. Am J Gastroenterol. 2020 Nov;115 (11):1812-20.","DOI":"10.14309\/ajg.0000000000000810"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021 Jan;56 (1):53-8.","DOI":"10.1080\/00365521.2020.1854848"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Khorrami S, Ginard D, Mar\u00edn-Jim\u00e9nez I, et al. Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016 Jul;22 (7):1662-9.","DOI":"10.1097\/MIB.0000000000000842"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017 May;45 (9):1232-43.","DOI":"10.1111\/apt.14016"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Yao J, Zhang H, Su T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn's disease: a retrospective real-world analysis. J Clin Med. 2023 Feb;12 (3):939.","DOI":"10.3390\/jcm12030939"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from Gemini 2. J Crohns Colitis. 2018 Apr;12 (5):621-6.","DOI":"10.1093\/ecco-jcc\/jjy019"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulizing Crohn's disease: results of the enterprise study. Gastroenterology. 2020 May;158 (6):S-193.","DOI":"10.1016\/S0016-5085(20)31166-5"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Chapuis-Biron C, Bourrier A, Nachury M, et al. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020 Apr;51 (7):719-27.","DOI":"10.1111\/apt.15665"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Rozal\u00e9n V, Par\u00e9s D, Sanchez E, et al. Advancement flap technique for anal fistula in patients with Crohn's disease: a systematic review of the literature. Cir Esp. 2017 Dec;95 (10):558-65.","DOI":"10.1016\/j.cireng.2017.09.008"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Stellingwerf ME, van Praag EM, Tozer PJ, et al. Systematic review and meta-analysis of endorectal advancement flap and ligation of the intersphincteric fistula tract for cryptoglandular and Crohn's high perianal fistulas. BJS Open. 2019 Jun;3 (3):231-41.","DOI":"10.1002\/bjs5.50129"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn's disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J Crohns Colitis. 2020 Aug;14 (8):1049-56.","DOI":"10.1093\/ecco-jcc\/jjaa004"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology. 2010 Jun;138 (7):2275-81.","DOI":"10.1053\/j.gastro.2010.02.013"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Sirany AME, Nygaard RM, Morken JJ. The ligation of the intersphincteric fistula tract procedure for anal fistula: a mixed bag of results. Dis Colon Rectum. 2015 Jun;58 (6):604-12.","DOI":"10.1097\/DCR.0000000000000374"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn's disease. Ann Surg. 2014 Dec;260 (6):1057-61.","DOI":"10.1097\/SLA.0000000000000479"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Qiu Y, Li C, Sheng S. Efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2024 Feb;15 (1):28.","DOI":"10.1186\/s13287-024-03637-z"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells. 2013 Nov;31 (11):2575-81.","DOI":"10.1002\/stem.1357"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. de la Portilla F, Alba F, Garc\u00eda-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I\/IIA clinical trial. Int J Colorectal Dis. 2013 Mar;28 (3):313-23.","DOI":"10.1007\/s00384-012-1581-9"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Dige A, Hougaard HT, Agnholt J, et al. Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn's disease. Gastroenterology. 2019 Jun;156 (8):2208-2216.e1.","DOI":"10.1053\/j.gastro.2019.02.005"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology. 2015 Oct;149 (4):918-27.e6.","DOI":"10.1053\/j.gastro.2015.06.014"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Barnhoorn MC, Wasser MNJM, Roelofs H, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. J Crohns Colitis. 2020 Jan;14 (1):64-70.","DOI":"10.1093\/ecco-jcc\/jjz116"}],"container-title":["Journal of the Anus, Rectum and Colon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/9\/1\/9_2024-067\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:55:00Z","timestamp":1737780900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/9\/1\/9_2024-067\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.23922\/jarc.2024-067","relation":{},"ISSN":["2432-3853"],"issn-type":[{"value":"2432-3853","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"article-number":"2024-067"}}